NCCN guidelines® insights head and neck cancers, version 2.2017 featured updates to the NCCN guidelines

David Adelstein; Maura L. Gillison; David G. Pfister; Sharon Spencer; Douglas Adkins; David M. Brizel; Barbara Burtness; Paul M. Busse; Jimmy J. Caudell; Anthony J. Cmelak; A. Dimitrios Colevas; David W. Eisele; Moon Fenton; Robert L. Foote; Jill Gilbert; Robert I. Haddad; Wesley L. Hicks; Ying J. Hitchcock; Antonio Jimeno; Debra Leizman; William M. Lydiatt; Ellie Maghami; Loren K. Mell; Bharat B. Mittal; Harlan A. Pinto; John A. Ridge; James Rocco; Cristina P. Rodriguez; Jatin P. Shah; Randal S. Weber; Matthew Witek; Frank Worden; Sue S. Yom; Weining Zhen; Jennifer L. Burns; Susan D. Darlow

doi:10.6004/JNCCN.2017.0101

NCCN guidelines^® insights head and neck cancers, version 2.2017 featured updates to the NCCN guidelines

David Adelstein, Maura L. Gillison, David G. Pfister, Sharon Spencer, Douglas Adkins, David M. Brizel, Barbara Burtness, Paul M. Busse, Jimmy J. Caudell, Anthony J. Cmelak, A. Dimitrios Colevas, David W. Eisele, Moon Fenton, Robert L. Foote, Jill Gilbert, Robert I. Haddad, Wesley L. Hicks, Ying J. Hitchcock, Antonio Jimeno, Debra LeizmanWilliam M. Lydiatt, Ellie Maghami, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, James Rocco, Cristina P. Rodriguez, Jatin P. Shah, Randal S. Weber, Matthew Witek, Frank Worden, Sue S. Yom, Weining Zhen, Jennifer L. Burns, Susan D. Darlow

Radiation Oncology

Research output: Contribution to journal › Article › peer-review

261 Scopus citations

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck Cancers provide treatment recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary sinuses, and salivary glands. Recommendations are also provided for occult primary of the head and neck (H&N), and separate algorithms have been developed by the panel for very advanced H&N cancers. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding the increase in human papillomavirus-associated oropharyngeal cancer and the availability of immunotherapy agents for treatment of patients with recurrent or metastatic H&N cancer.

Original language	English (US)
Pages (from-to)	761-770
Number of pages	10
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	15
Issue number	6
DOIs	https://doi.org/10.6004/JNCCN.2017.0101
State	Published - Jun 2017

Funding

This activity is supported by educational grants from Astellas, AstraZeneca, Celldex Therapeutics, Clovis Oncology, Genomic Health, Inc., Kyowa Hakko Kirin, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation, and NOVOCURE. This activity is supported by an independent educational grant from Merck Co., Inc.

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.6004/JNCCN.2017.0101

Cite this

Adelstein, D., Gillison, M. L., Pfister, D. G., Spencer, S., Adkins, D., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Eisele, D. W., Fenton, M., Foote, R. L., Gilbert, J., Haddad, R. I., Hicks, W. L., Hitchcock, Y. J., Jimeno, A., ... Darlow, S. D. (2017). NCCN guidelines^® insights head and neck cancers, version 2.2017 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 15(6), 761-770. https://doi.org/10.6004/JNCCN.2017.0101

@article{dd665d6fc3bc4c71ba92bb5407c60dc9,

title = "NCCN guidelines{\textregistered} insights head and neck cancers, version 2.2017 featured updates to the NCCN guidelines",

abstract = "The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck Cancers provide treatment recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary sinuses, and salivary glands. Recommendations are also provided for occult primary of the head and neck (H&N), and separate algorithms have been developed by the panel for very advanced H&N cancers. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding the increase in human papillomavirus-associated oropharyngeal cancer and the availability of immunotherapy agents for treatment of patients with recurrent or metastatic H&N cancer.",

author = "David Adelstein and Gillison, {Maura L.} and Pfister, {David G.} and Sharon Spencer and Douglas Adkins and Brizel, {David M.} and Barbara Burtness and Busse, {Paul M.} and Caudell, {Jimmy J.} and Cmelak, {Anthony J.} and Colevas, {A. Dimitrios} and Eisele, {David W.} and Moon Fenton and Foote, {Robert L.} and Jill Gilbert and Haddad, {Robert I.} and Hicks, {Wesley L.} and Hitchcock, {Ying J.} and Antonio Jimeno and Debra Leizman and Lydiatt, {William M.} and Ellie Maghami and Mell, {Loren K.} and Mittal, {Bharat B.} and Pinto, {Harlan A.} and Ridge, {John A.} and James Rocco and Rodriguez, {Cristina P.} and Shah, {Jatin P.} and Weber, {Randal S.} and Matthew Witek and Frank Worden and Yom, {Sue S.} and Weining Zhen and Burns, {Jennifer L.} and Darlow, {Susan D.}",

note = "Publisher Copyright: {\textcopyright} National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.",

year = "2017",

month = jun,

doi = "10.6004/JNCCN.2017.0101",

language = "English (US)",

volume = "15",

pages = "761--770",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "6",

}

Adelstein, D, Gillison, ML, Pfister, DG, Spencer, S, Adkins, D, Brizel, DM, Burtness, B, Busse, PM, Caudell, JJ, Cmelak, AJ, Colevas, AD, Eisele, DW, Fenton, M, Foote, RL, Gilbert, J, Haddad, RI, Hicks, WL, Hitchcock, YJ, Jimeno, A, Leizman, D, Lydiatt, WM, Maghami, E, Mell, LK, Mittal, BB, Pinto, HA, Ridge, JA, Rocco, J, Rodriguez, CP, Shah, JP, Weber, RS, Witek, M, Worden, F, Yom, SS, Zhen, W, Burns, JL & Darlow, SD 2017, 'NCCN guidelines^® insights head and neck cancers, version 2.2017 featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 15, no. 6, pp. 761-770. https://doi.org/10.6004/JNCCN.2017.0101

TY - JOUR

T1 - NCCN guidelines® insights head and neck cancers, version 2.2017 featured updates to the NCCN guidelines

AU - Adelstein, David

AU - Gillison, Maura L.

AU - Pfister, David G.

AU - Spencer, Sharon

AU - Adkins, Douglas

AU - Brizel, David M.

AU - Burtness, Barbara

AU - Busse, Paul M.

AU - Caudell, Jimmy J.

AU - Cmelak, Anthony J.

AU - Colevas, A. Dimitrios

AU - Eisele, David W.

AU - Fenton, Moon

AU - Foote, Robert L.

AU - Gilbert, Jill

AU - Haddad, Robert I.

AU - Hicks, Wesley L.

AU - Hitchcock, Ying J.

AU - Jimeno, Antonio

AU - Leizman, Debra

AU - Lydiatt, William M.

AU - Maghami, Ellie

AU - Mell, Loren K.

AU - Mittal, Bharat B.

AU - Pinto, Harlan A.

AU - Ridge, John A.

AU - Rocco, James

AU - Rodriguez, Cristina P.

AU - Shah, Jatin P.

AU - Weber, Randal S.

AU - Witek, Matthew

AU - Worden, Frank

AU - Yom, Sue S.

AU - Zhen, Weining

AU - Burns, Jennifer L.

AU - Darlow, Susan D.

N1 - Publisher Copyright: © National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

PY - 2017/6

Y1 - 2017/6

N2 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck Cancers provide treatment recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary sinuses, and salivary glands. Recommendations are also provided for occult primary of the head and neck (H&N), and separate algorithms have been developed by the panel for very advanced H&N cancers. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding the increase in human papillomavirus-associated oropharyngeal cancer and the availability of immunotherapy agents for treatment of patients with recurrent or metastatic H&N cancer.

AB - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck Cancers provide treatment recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary sinuses, and salivary glands. Recommendations are also provided for occult primary of the head and neck (H&N), and separate algorithms have been developed by the panel for very advanced H&N cancers. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding the increase in human papillomavirus-associated oropharyngeal cancer and the availability of immunotherapy agents for treatment of patients with recurrent or metastatic H&N cancer.

UR - http://www.scopus.com/inward/record.url?scp=85036501504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036501504&partnerID=8YFLogxK

U2 - 10.6004/JNCCN.2017.0101

DO - 10.6004/JNCCN.2017.0101

M3 - Article

C2 - 28596256

AN - SCOPUS:85036501504

SN - 1540-1405

VL - 15

SP - 761

EP - 770

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 6

ER -